Europe — EMA
Olmesartanmedoxomil Amlodipin Beta (Olmesartan Medoxomil, Amlodipine)
GNH USA supplies Olmesartanmedoxomil Amlodipin Beta (Olmes5), a Angiotensin II receptor blocker for hypertension and cardiovascular risk reduction.
Request sourcing
What is Olmesartan Medoxomil, Amlodipine?
Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil Amlodipin Beta, is an Angiotensin II receptor blocker (ARBs) presented as a strength/form for oral use. It treats hypertension and may be used in adults requiring blood pressure control. GNH USA supplies Olmesartanmedoxomil Amlodipin Beta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Olmesartanmedoxomil Amlodipin Beta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
What is Olmesartan Medoxomil, Amlodipine used for?
Olmesartan medoxil combined with amlodipine acts on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure. - Hypertension: improves blood pressure control and reduces cardiovascular risk. - Chronic kidney disease with hypertension: helps protect renal function by maintaining target blood pressure. - Heart failure with reduced ejection fraction (as adjunct therapy): supports symptomatic management alongside standard heart‑failure drugs.
What are the side effects of Olmesartan Medoxomil, Amlodipine?
Olmesartanmedoxomil Amlodipin Beta is generally well tolerated, but adverse reactions can occur.
Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially on standing. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Nasal congestion: mild blockage.
Serious or Rare Side Effects: - Angio‑edema: swelling of face, lips, or throat. - Severe hypotension: marked drop in blood pressure. - Hepatic injury: abnormal liver function tests. - Hyperkalemia: elevated potassium levels. - Acute kidney injury: sudden decline in renal function. - Myocardial infarction: rare but reported cardiac event.
What precautions apply to Olmesartan Medoxomil, Amlodipine?
When prescribing Olmesartanmedoxil Amlodipin Beta, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function regularly. - Hepatic impairment: use with caution and monitor liver enzymes. - Electrolyte disturbances: check potassium levels periodically. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging.
What does Olmesartan Medoxomil, Amlodipine interact with?
Olmesartanmedoxil Amlodipin Beta may interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs. - Strong CYP3A4 inhibitors: may increase amlodipine levels. - Potassium‑rich supplements: risk of hyper‑kalemia.
Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Lithium: may increase serum lithium concentrations. - Antidiabetic drugs: monitor blood glucose as blood pressure changes can affect glycemic control.
